title: Overcoming trastuzumab resistance with nordihydroguaiaretic acid?
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Ozden
authors.initials: O
authors.lastname: Altundag
authors.forename: Ebru
authors.initials: E
authors.lastname: Karakaya
authors.forename: Serap
authors.initials: S
authors.lastname: Akyurek
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000037:antagonists & inhibitors*; D009637:Masoprocol / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007334:Insulin-Like Growth Factor I; D009637:Masoprocol; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab